BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
BioLineRx Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 80.5%
- Operating margin
- -871.8%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 1.20
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 33.8%
Valuation
- P/E ratio
- –
- Price to sales
- 4471.46
- Price to book
- 383.17
- Dividend yield
- –